Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 11/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6519608 | 0.84 | HCRTR1 (0.41) | HCRTR1HCRTR2OPRK1 | |
| SCHEMBL1119706 | 0.84 | HCRTR1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL6523847 | 0.84 | NPC1 (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL9899468 | 0.78 | HCRTR1 (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL9899444 | 0.77 | SSTR4 (0.32) | HCRTR1HCRTR2 | |
| SCHEMBL9898617 | 0.74 | IL1B (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL19418484 | 0.74 | CRHR1 (0.54) | CRHR1TRPA1ABL1CYP2D6DPP4 | |
| SCHEMBL9895397 | 0.73 | LNPEP (0.34) | HCRTR2 | |
| SCHEMBL9928405 | 0.73 | MAPK1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL16530784 | 0.71 | IDH1 (0.34) | CRHR1HCRTR1TRPA1CYP2D6DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470525-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | Glaxo Group Limited (GB) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, OXTR | CRHR1 13/4885HCRTR1 2/4885TRPA1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.